FY2027 EPS Estimates for Aytu BioPharma Cut by Analyst

Aytu BioPharma Inc. (NASDAQ:AYTU) – Ascendiant Capital Markets reduced their FY2027 earnings per share (EPS) estimates for shares of Aytu BioPharma in a research note issued on Wednesday, June 10th. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will earn $0.25 per share for the year, down from their prior estimate of $0.30. Ascendiant Capital Markets has a “Buy” rating and a $14.50 price target on the stock. The consensus estimate for Aytu BioPharma’s current full-year earnings is ($0.69) per share. Ascendiant Capital Markets also issued estimates for Aytu BioPharma’s Q4 2027 earnings at $0.16 EPS.

Several other research analysts also recently commented on the company. Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Wednesday, April 8th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $9.83.

Aytu BioPharma Stock Down 2.2%

AYTU stock opened at $2.19 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.00 and a current ratio of 1.12. The company has a market capitalization of $23.50 million, a price-to-earnings ratio of -0.48 and a beta of 0.24. Aytu BioPharma has a fifty-two week low of $1.65 and a fifty-two week high of $3.07. The stock has a fifty day moving average of $2.40 and a 200-day moving average of $2.46.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The business had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million.

Institutional Trading of Aytu BioPharma

A number of hedge funds have recently bought and sold shares of the company. FNY Investment Advisers LLC increased its stake in Aytu BioPharma by 24,207.7% in the 4th quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock worth $82,000 after purchasing an additional 31,470 shares during the period. Arete Wealth Advisors LLC purchased a new position in Aytu BioPharma in the 1st quarter worth approximately $135,000. Rothschild Wealth LLC purchased a new position in Aytu BioPharma in the 4th quarter worth approximately $52,000. Dimensional Fund Advisors LP purchased a new position in Aytu BioPharma in the 3rd quarter worth approximately $58,000. Finally, Two Sigma Investments LP increased its stake in Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock worth $129,000 after purchasing an additional 33,701 shares during the period. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.